OTLK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 16:00):

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications...

Stats
Today's Volume	270 704
Average Volume	650 302
Market Cap	176.34M
EPS	$0 ( 2024-02-13 )
Next earnings date	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.04
ATR14	$0.0220 (0.27%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-15	Syntone Ventures Llc	Buy	714 286	Common Stock
2024-04-15	Syntone Ventures Llc	Buy	1 071 429	Warrant (Right to Buy)
2024-03-28	Haddadin Yezan Munther	Buy	1 882	Common Stock
2024-03-20	Trenary C Russell Iii	Buy	455 000	Stock Option (Right to Buy)
2024-03-20	Evanson Jeff	Buy	25 000	Stock Option (Right to Buy)

INSIDER POWER
87.71
Last 99 transactions
Buy: 132 469 020 \| Sell: 31 433 684

Volume Correlation

Long: 0.15 (neutral)

Short: -0.69 (moderate negative)

Signal:(54.93) Neutral

Outlook Therapeutics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Outlook Therapeutics Inc Correlation - Currency/Commodity

0.02
( neutral )

0.16
( neutral )

0.00
( neutral )

-0.18
( neutral )

0.63
( weak )

0.05
( neutral )

Outlook Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-44 188.00 (0.00 %)
EPS:	$-4.72

Q4	2023
Revenue:	$0
Gross Profit:	$-11 217.00 (0.00 %)
EPS:	$-1.000

Q3	2023
Revenue:	$0
Gross Profit:	$-11 192.00 (0.00 %)
EPS:	$-1.610

Q2	2023
Revenue:	$0
Gross Profit:	$-11 001.00 (0.00 %)
EPS:	$-0.520

Financial Reports:

No articles found.

Outlook Therapeutics Inc

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.